Clinical Trial SuccessThe trial achieved statistical significance in the primary endpoint of overall response rate, showing better results for tovecimig + paclitaxel compared to paclitaxel alone.
Financial HealthCompass Therapeutics ended the quarter financially strong with $113 million, expected to provide runway into 2027.
Pipeline DevelopmentThe remainder of the pipeline is on track, with plans to report initial Phase 1 data for CTX-8371 and file an IND for CTX-10726.